Awakn Life Sciences (NEOE:AWKN) Debt-to-Revenue

: 1.26 (As of Oct. 2022)

View and export this data going back to 2021. Start your Free Trial

Debt-to-Revenue measures a company's ability to pay off its debt.

Awakn Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2022 was C$0.37 Mil. Awakn Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2022 was C$1.80 Mil. Awakn Life Sciences's annualized Revenue for the quarter that ended in Oct. 2022 was C$1.72 Mil. Awakn Life Sciences's annualized Debt-to-Revenue for the quarter that ended in Oct. 2022 was 1.26.

Awakn Life Sciences Debt-to-Revenue Historical Data

The historical data trend for Awakn Life Sciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Awakn Life Sciences Annual Data

Trend

Jan22

Debt-to-Revenue

7.67

Awakn Life Sciences Quarterly Data
	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22
Debt-to-Revenue			14.03	2.22	1.69	1.19	1.26

Competitive Comparison

For the Biotechnology subindustry, Awakn Life Sciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Awakn Life Sciences Debt-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Awakn Life Sciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Awakn Life Sciences's Debt-to-Revenue falls in comparison to its industry or sector. The grey bar indicates the Debt-to-Revenue's extreme value range as defined by GuruFocus.

Awakn Life Sciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Awakn Life Sciences's Debt-to-Revenue for the fiscal year that ended in Jan. 2022 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.356	+	1.453)	/	0.236
	=	7.67

Awakn Life Sciences's annualized Debt-to-Revenue for the quarter that ended in Oct. 2022 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.37	+	1.799)	/	1.724
	=	1.26

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Oct. 2022) Revenue data.

Awakn Life Sciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Awakn Life Sciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Awakn Life Sciences (NEOE:AWKN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Awakn Life Sciences Corp (NEOE:AWKN) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

AWKNF:USA 954:Germany

Address

301?217 Queen Street West, Toronto, ON, CAN, M5V 0R2

Website

https://www.awaknlifesciences.com

Awakn Life Sciences Corp is a Canadian biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat addiction. It is engaged in researching and developing psychedelic drugs, therapies, and enabling technologies to treat addiction and delivering psychedelic treatments for addiction in clinics in the UK and EU.

Awakn Life Sciences (NEOE:AWKN) Headlines

No Headlines